Key result
IV dipyridamole induces pacing ischemia at a ~13 bpm lower heart rate than nitroglycerin.
Why the study?
The comparative effects of intravenous dipyridamole and sublingual nitroglycerin on coronary hemodynamics and myocardial metabolism in patients with significant coronary obstruction were not well characterized.
Does intravenous dipyridamole compared to sublingual nitroglycerin alter coronary hemodynamics and tolerance to pacing-induced ischemia in patients with significant coronary obstruction?
Does intravenous dipyridamole compared to sublingual nitroglycerin alter coronary hemodynamics and tolerance to pacing-induced ischemia in patients with significant coronary obstruction?
Intravenous dipyridamole reduces tolerance to pacing-induced ischemia compared to sublingual nitroglycerin in patients with coronary artery disease, likely due to coronary steal.
May warrant caution with dipyridamole in paced CAD patients; leaves open coronary steal mechanisms pending prospective validation.
The effects of intravenous dipyridamole (20 mg) and sublingual nitroglycerin (0.6 mg) were compared at rest and during rapid atrial pacing in patients with significant coronary obstruction. Dipyridamole, which had no significant effect on resting systolic blood pressure, caused a significant increase in coronary sinus flow (CSF) and reduction of coronary vascular resistance (CVR) and arterial-coronary sinus oxygen difference (AO2CSO2 delta), whereas nitroglycerin reduced resting systolic pressure but had no significant effect on CSF, CVR, or AO2-CSO2 delta. Although theses effects of dipyridamole and nitroglycerin on resting systolic pressure, CSF, CVR, and AO2-CSO2 delta were qualitatively similar during rapid atrial pacing, the onset of chest pain and ischemic ECG changes occurred at a lower heart rate following dipyridamole (136 +/- 5 beats/min) than following nitroglycerin (149 +/- 6 beats/min, p less than 0.01). However, maximal double product and myocardial oxygen consumption achieved during pacing were similar following both dipyridamole and nitroglycerin and were less than control pacing values. Coronary dilatation following dipyridamole appears to reduce tolerance to pacing-induced ischemia probably by maldistribution of coronary flow away from ischemic myocardium. Nitroglycerin differs from dipyridamole by improving tolerance to pacing; however, this difference appears to be due to systemic vasodilator effects of nitroglycerin rather than to enhancement of flow to ischemic myocardium.
No takes yet. Share an insight, caveat, or question.
Arrotti et al. (1980) studied Coronary artery disease. Intravenous dipyridamole vs. Sublingual nitroglycerin (0.6 mg) was evaluated on Heart rate at onset of chest pain and ischemic ECG changes during rapid atrial pacing (p=<0.01). Intravenous dipyridamole caused chest pain and ischemic ECG changes at a lower heart rate (136 beats/min) than sublingual nitroglycerin (149 beats/min, p<0.01) during rapid atrial pacing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: